Population pharmacokinetic analysis of lanicemine (AZD6765), an NMDA channel blocker, in healthy subjects and patients with major depressive disorder
Author:
Affiliation:
1. Quantitative Clinical Pharmacology; AstraZeneca Pharmaceuticals LP; Wilmington DE USA
2. Quantitative Clinical Pharmacology; AstraZeneca LP; Waltham MA USA
Funder
AstraZeneca Pharmaceuticals LP
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12541/fullpdf
Reference22 articles.
1. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects;Sanacora;Mol Psychiatry,2014
2. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study;Lees;Stroke,2001
3. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression;Zarate;Biol Psychiatry,2013
4. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature;Ferrari;Psychol Med,2013
5. Prevalence of treatment-resistant depression in primary care: cross-sectional data;Thomas;Br J Gen Pract,2013
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents;Frontiers in Pharmacology;2022-06-17
2. Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review;Frontiers in Psychiatry;2022-05-26
3. Novel drug developmental strategies for treatment‐resistant depression;British Journal of Pharmacology;2022-01-26
4. Modulating Neuroplasticity: Lessons Learned from Antidepressants and Emerging Novel Therapeutics;Current Treatment Options in Psychiatry;2021-10-12
5. Enhancing Clinical Trials Through Synergistic Gamma Power Analysis;Frontiers in Psychiatry;2020-06-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3